The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.
Study Type
OBSERVATIONAL
Enrollment
44
University Medical Center Göttingen
Göttingen, Lower Saxony, Germany
Helios Albert-Schweitzer-Klinik Northeim
Northeim, Lower Saxony, Germany
Soluble serum Syndecan-1 in ng/ml
Time frame: 6 months
Underlying disease
Time frame: 6 months
Patient age
Time frame: 6 Months
Disease activity in Inflammatory bowel disease
Time frame: 6 Months
Calprotectin in stool
Time frame: 6 Months
Leucocyte blood count
Time frame: 6 Months
CRP in serum
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.